European Drug Report 2020

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) launched today the European Drug Report 2020: Trends and Developments. In its latest annual review – marking 25 years of monitoring – the agency describes the drug situation at the end of 2019, along with recent changes brought by the COVID-19 pandemic in early 2020.

High availability across all drug types, drug production within Europe and highly potent substances are among the concerns addressed today. New developments highlighted in the report include: record cocaine, and large heroin, seizures; a scaling up of synthetic drug production; and concerns around high-potency cannabis, new synthetic opioids and ecstasy tablets containing high levels of MDMA. Drawing on new EMCDDA rapid studies (Spring 2020), the report also reviews COVID-19 disruption to drug use and the market, which could have long-term implications for Europe’s drug services and law enforcement agencies. There are fears that innovative drug distribution models developed during lockdown, along with the economic impact of the pandemic on vulnerable communities, will add to the challenges already posed by an abundant supply of drugs.

The following ‘Key issues’ have been identified in this year’s analysis:

  • Large drug shipments are increasingly intercepted
  • Cocaine’s role in Europe’s drug problem is increasing
  • Potential for increased heroin use and existing harms raise concerns
  • Understanding the public health impact of high-potency cannabis and new products
  • Increased and diverse drug production within Europe
  • Continuing availability of high-strength MDMA products highlights need for greater user awareness
  • Growing complexity in the drug market poses regulatory challenges and health risks
  • Need for new tools and innovative strategies to support the scaling-up of hepatitis C treatment
  • Drug overdose is increasingly associated with an ageing population
  • New psychoactive substances (NPS) have become a more persistent problem
  • Appearance of novel synthetic opioids is a worrying example of continuing market adaptability

To read the Report and get more information, follow this link>>>.

Presentations from the launch are available at Youtube:

 

European Drug Report 2020 to be released on 22 September

The EU drugs agency (EMCDDA) launches its European Drug Report 2020: Trends and Developments in a live online media event on 22 September.

In this latest annual review – marking 25 years of monitoring – the EMCDDA describes the drug situation at the end of 2019, along with recent changes brought by the COVID-19 pandemic in early 2020.

The report provides a comprehensive analysis of patterns emerging across the EU, Turkey and Norway in the areas of drug supply, illicit drug use and associated public health problems. National data sets are also provided across these themes and on key harm-reduction interventions. In a new format, chapters are organised primarily by drug type and by related harms.

Accompanying the report this year will be a Key Issues summary (in 24 languages), presenting a selection of the main findings from the latest analysis, chosen for their policy relevance and general interest. The 2020 Statistical Bulletin, containing the European dataset underpinning the report, will also be available.

Attend the live online media event to hear the key issues and latest analysis on 22 September 2020 at 10.00 (Lisbon), 11.00 CET.

Further details will be available in the run-up to the launch at: www.emcdda.europa.eu/edr2020.